Evidence map›Paper›PMID 36926422›Full record

ArticleAdvanced biomedical research2023

Thalidomide for the Treatment of COVID-19 Pneumonia: A Randomized Controlled Clinical Trial.

Babak Amra, Farzaneh Ashrafi, Mehdi Torki, Marzieh Hashemi, Mohamad Shirzadi, Forogh Soltaninejad, Somayeh Sadeghi, Mehrzad Salmasi, Ramin Sami, Ali Darakhshandeh and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced biomedical research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Babak AmraBamdad Respiratory and Sleep Research Center, Department of Internal Medicine, Pulmonary and Sleep Ward, Isfahan University of Medical Sciences, Isfahan, Iran.
Farzaneh AshrafiDepartment of Hematology Oncology, Isfahan University of Medical Sciences, Isfahan, Iran.
Mehdi TorkiDepartment of Internal Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Marzieh HashemiDepartment of Internal Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Mohamad ShirzadiDepartment of Internal Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Forogh SoltaninejadBamdad Respiratory and Sleep Research Center, Department of Internal Medicine, Pulmonary and Sleep Ward, Isfahan University of Medical Sciences, Isfahan, Iran.
Somayeh SadeghiDepartment of Internal Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Mehrzad SalmasiDepartment of Internal Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Ramin SamiDepartment of Internal Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Ali DarakhshandehDepartment of Internal Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Maryam NasirianDepartment of Epidemiology, Isfahan University of Medical Sciences, Isfahan, Iran.
Samaneh PourajamDepartment of Internal Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Isfahan University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Coronavirus disease 2019 has become a public health concern with a high number of fatalities. Thalidomide can target inflammatory mediators and decrease inflammation in SARS-CoV-2. Materials and Methods: An open-label, randomized controlled trial was conducted on patients with compatible lung high-resolution computed tomography scan for COVID-19 pneumonia and moderate involvement. Childbearing-age women were excluded. A total of 20 patients in the control group receiving usual treatment were compared with 26 patients in the case group who in addition to the same regimen also received thalidomide. The primary outcome was time for clinical recovery (TTCR) and intensive-care unit (ICU) admission. Results: From April 25 to August 8, 2020, based on the inclusion criteria, 47 patients were assigned to the study. Patients receiving thalidomide had a mean TTCR of days 5.5 (95% confidence interval [CI], 0.7-10.3), as compared with days 5.3 (95% CI, 1.7-8.9) with control (odds ratio 0.01; 95% CI, -1.58-1.59, Conclusion: This study investigated the effects of thalidomide to treat moderate COVID-19 clinical outcomes. The results established that this drug regimen did not add more effect to usual treatment for moderate COVID-19 pneumonia.

Indexed as

COVID-19intensive-care unit (ICU)length of staypneumoniathalidomide

Identifiers

PMID36926422
PMCPMC10012021
OpenAlexW4319020451

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.